|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/29/18 AVRA Medical Robotics, Inc. 10-K 12/31/17 44:2.2M S2 Filings LLC/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 339K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 20K
3: EX-32.1 Certification -- §906 - SOA'02 HTML 16K
10: R1 Document and Entity Information HTML 41K
11: R2 Balance Sheets HTML 73K
12: R3 Balance Sheets (Parenthetical) HTML 32K
13: R4 Statements of Operations HTML 49K
14: R5 Statements of Cash Flows HTML 72K
15: R6 Statement of Shareholders' Equity (Deficit) HTML 52K
16: R7 Condensed Financial Statements HTML 21K
17: R8 Summary of Significant Accounting Policies HTML 31K
18: R9 Recent Accounting Pronouncements HTML 21K
19: R10 Research Collaboration Agreement HTML 21K
20: R11 Accrued Expenses HTML 16K
21: R12 Promissory Notes HTML 18K
22: R13 Income Taxes HTML 20K
23: R14 Stockholders' Equity (Deficit) HTML 21K
24: R15 2016 Incentive Stock Plan HTML 24K
25: R16 Employment Agreements HTML 20K
26: R17 Earnings Per Share HTML 16K
27: R18 Lease Commitment HTML 17K
28: R19 Subsequent Events HTML 19K
29: R20 Summary of Significant Accounting Policies HTML 64K
(Policies)
30: R21 Research Collaboration Agreement (Table) HTML 18K
31: R22 Summary of Significant Accounting Policies HTML 19K
(Details Narrative)
32: R23 Research Collaboration Agreement (Details) HTML 21K
33: R24 Research Collaboration Agreement (Details HTML 25K
Narrative)
34: R25 Accrued Expenses (Details Narrative) HTML 18K
35: R26 Promissory Notes (Details Narrative) HTML 47K
36: R27 Income Taxes (Details Narrative) HTML 26K
37: R28 Stockholders' Equity (Deficit) (Details Narrative) HTML 69K
38: R29 2016 Incentive Stock Plan (Details Narrative) HTML 55K
39: R30 Employment Agreements (Details Narrative) HTML 40K
40: R31 Lease Commitment (Details Narrative) HTML 16K
41: R32 Subsequent Events (Details Narrative) HTML 27K
43: XML IDEA XML File -- Filing Summary XML 74K
42: EXCEL IDEA Workbook of Financial Reports XLSX 39K
4: EX-101.INS XBRL Instance -- cik0001676163-20171231 XML 359K
6: EX-101.CAL XBRL Calculations -- cik0001676163-20171231_cal XML 87K
7: EX-101.DEF XBRL Definitions -- cik0001676163-20171231_def XML 230K
8: EX-101.LAB XBRL Labels -- cik0001676163-20171231_lab XML 452K
9: EX-101.PRE XBRL Presentations -- cik0001676163-20171231_pre XML 361K
5: EX-101.SCH XBRL Schema -- cik0001676163-20171231 XSD 79K
44: ZIP XBRL Zipped Folder -- 0001615774-18-002200-xbrl Zip 56K
Exhibit 31.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
AND CHIEF FINANCIAL OFFICER PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Barry F. Cohen, Chief Executive Officer and Acting Chief Financial Officer of Avra Medical Robotics, Inc., a Florida corporation (the “Registrant”), certify that:
1. I have reviewed this Form 10-K for the fiscal year ended December 31, 2017 of the Registrant;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;
4. I, as the Registrant’s Chief Executive Office and Acting Chief Financial Officer, am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15 (f) and 15d-15(f)) for the registrant and have:
| a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
| b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
| c) | Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
| d) | Disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and |
5. I, as the Registrant’s Chief Executive Office and Acting Chief Financial Officer, have disclosed, based on my most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):
| a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and |
| b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting. |
| Date: March 29, 2018 |
| AVRA MEDICAL ROBOTICS, INC. | |||
| By: | /s/ Barry F. Cohen | ||
| Barry F. Cohen, Chief Executive Officer and Acting Chief Financial Officer | |||
| (Principal Executive, Financial and Accounting Officer) | |||
C:
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/29/18 | None on these Dates | ||
| For Period end: | 12/31/17 | |||
| List all Filings | ||||